The efficacy of front-line brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (A + CHP) in previously untreated patients with CD30-positive PTCL has been demonstrated in the phase 3 ECHELON-2 study, which enrolled 452 patients with CD30 + PTCL, of whom 316 (70%) had sALCL [7]. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.